Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 2/20 | 0.49 |
| ▸ | SLC34A1 | Q06495 | 12/20 | 0.43 |
| ▸ | FPR1 | P21462 | 1/20 | 0.37 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4239653 | 0.82 | AR (0.54) | ARSLC34A1NR3C1MEN1POLB | |
| SCHEMBL4237188 | 0.79 | AR (0.58) | ARSLC34A1FPR1 | |
| SCHEMBL23013056 | 0.78 | AR (0.43) | ARSLC34A1FPR1NR3C1MEN1 | |
| SCHEMBL4296254 | 0.77 | AR (0.42) | ARSLC34A1NR3C1MEN1KMT2A | |
| SCHEMBL5904635 | 0.77 | BRAF (0.42) | ARFPR1NR3C1 | |
| SCHEMBL4307303 | 0.76 | AR (0.55) | ARSLC34A1FPR1 | |
| SCHEMBL20075148 | 0.76 | SLC34A1 (0.53) | ARSLC34A1NR3C1MEN1KMT2A | |
| SCHEMBL20037190 | 0.75 | SMN1; SMN2 (0.62) | ARSLC34A1ALDH1A1CYP2A6 | |
| SCHEMBL4236666 | 0.75 | AR (0.64) | ARSLC34A1MEN1KMT2A | |
| SCHEMBL4233402 | 0.72 | SLC34A1 (0.54) | ARSLC34A1FPR1NR3C1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270361-A1 | Substituted pyrazole derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090270361-A1 | Substituted pyrazole derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-29 | — | — | US | disclosed |
| WO-2009119880-A1 | SUBSTITUTED PYRAZOLE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270361-A1 | Substituted pyrazole derivatives and use thereof | CBR3, CBR1, NOX5 | AR 622/4885SLC34A1 1375/4885FPR1 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.